gaining weight tirzepatide NEW: Stopping (Mounjaro) leads patients to gain back the majority of lost weight. - Patients on tirzepatide lost 21% of their body in 36 months Mounjaro (Tirzepatide) for Medical Weight

Start your Semaglutide program today Join patients across the U.S

If you frequently miss doses or have any questions about your treatment plan, dont hesitate to consult your healthcare provider

Exploration of New Indications The versatility of semaglutide, evidenced by its impact on weight management and glycemic control, raises the question of its potential in treating other conditions

Analogous to the gut-pancreas connection, which identified the incretin effect relating to insulin secretion, early studies proposed the existence of a so-called gut-kidney axis

Zepbound (tirzepatide) is a prescription medication approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

As such, there is growing interest in repurposing medications with novel mechanisms of action